Mc Ilrath & Eck, LLC Cyclacel Pharmaceuticals, Inc. Call Options Transaction History

Mc Ilrath & Eck, LLC

  • $494 Million
  • Q2 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

About Cyclacel Pharmaceuticals, Inc.

CYCC Quotes by TradingView
  • Ticker CYCC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,539,200
  • Market Cap $7.9M
  • Description
  • Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...
More about CYCC
Track This Portfolio

Track Mc Ilrath & Eck, LLC Portfolio

Follow Mc Ilrath & Eck, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mc Ilrath & Eck, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mc Ilrath & Eck, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email